Roxane Laboratories (Columbus, OH) began in 1885 as Columbus Pharmacal, a small, regional pharmaceutical manufacturer. In 1959, Columbus Pharmacal was purchased by Philips of the Netherlands, and the name was changed from Columbus Pharmacal to Philips Roxane. In 1978, it was acquired by Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and the name changed to Roxane Laboratories as it is known today.
Roxane Laboratories' headquarters is in a modern 600,000 sq-ft manufacturing and laboratory facility. The facility spans 70 acres, currently employs more than 1000 individuals, and is known as the heart of Boehringer Ingelheim's prescription pharmaceutical manufacturing in North America.
Roxane Laboratories is a recognized leader in distributing high quality products, selecting special markets and creating unique products to fill specific customer needs. In response to this strategy, Roxane pioneered unit-dose packaging tablets, capsules, and oral solutions for hospital pharmacies. In addition, among Roxane's many innovative firsts were Intensol™ (concentrated solution) and Unit Dose Vials for inhalation. In recent years exciting new development strategies have enabled Roxane Laboratories unique and successful product launches including Fluticasone, Oxcarbazepine, and Acarbose.
|Marketed by Roxane Laboratories (Columbus, Ohio)|
Currently, Roxane Laboratories markets more than 75 medications in nearly 300 package sizes focusing on an expanding line of multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release, and controlled-release tablets; nasal sprays; CII narcotics; and potent compounds (cytotoxics).
Judy Waterer, associate director of marketing, calls this "a very exciting period in our corporate evolution as a multisource supplier dedicated to pharmacists' needs. We demonstrate multifaceted technical capabilities with our existing portfolio of more than 200 items. Retail pharmacy should see our introductions as further demonstrations of our proven versatility in product and dosage forms."
In addition, the company has a robust development pipeline, supplemented with 16 to 20 Abbreviated New Drug Applications (ANDAs) filings annually. These products include potent compounds, nasals, controlled release, clinical barrier, controlled narcotics, and unique technology products.
"We've been ramping up our development for several years. Now the pipeline is starting to spawn new ANDA approvals and the subsequent availability of new generic products," said Paul Kersten, general manager of marketing and sales, noting that the company expects to file at least 18 ANDAs this year.
Today and into the future, Roxane Laboratories will continue to focus on being a first to market generic pharmaceuticals provider striving to meet the changing needs of our customers and their patients.
For more information, visit www.roxane.com.